Authors
Maria Rossello-Gelabert, Camino Garcia-Blasco, Jose Javier Aguirre, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez
Published in
Trends in biotechnology. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Ulcerative colitis (UC) is a chronic, immune-mediated disorder characterized by recurrent mucosal inflammation and epithelial damage. Its incidence is rising, while current therapies fail to achieve durable remission due to limited efficacy or adverse effects. Cell-free approaches based on the mesenchymal stromal cell (MSC) secretome offer an alternative with improved safety and scalability. In this study, we present Prime-LS, an excipient-free, off-the-shelf MSC-secretome biologic that retains immunomodulatory activity without cryoprotectants. Prime-LS preserves soluble immunomodulatory mediators and extracellular vesicle populations with characteristic surface markers and vesicular morphology following lyophilization and reconstitution, while forming a homogeneous formulation without visible precipitation or detectable aggregate formation. In vitro, Prime-LS suppressed proliferation of peripheral blood mononuclear cells, while in vivo subcutaneous dosing in a murine colitis model prevented disease onset, preserved mucosal integrity, and normalized inflammation. Together, these findings support Prime-LS as a stable, functionally preserved MSC-secretome formulation with potential for further translational development in UC and other immune-mediated diseases.
PMID:
43045542
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0